Literature DB >> 8757568

Effect of recombinant human erythropoietin on insulin, amino acid, and lipid metabolism in uremia.

R H Mak1.   

Abstract

OBJECTIVE: To determine whether anemia is important in the pathogenesis of metabolic abnormalities in insulin, amino acid, and lipid metabolism in uremia.
METHODS: Twelve adolescents (15 +/- 1 years of age) undergoing long-term dialysis were studied before and after correction of their anemia by human recombinant erythropoietin at a mean interval of 6 months. Six patients received hemodialysis, and six received continuous-cycling peritoneal dialysis. Insulin sensitivity was measured by the euglycemic clamp technique and insulin secretion by the hyperglycemic clamp technique in these patients.
RESULTS: Hematocrit increased from 0.219 +/- 0.006 to 0.344 +/- 0.007 (p <0.01). Ferritin concentration did not change significantly (11,252 +/- 356 mg/dl to 785 +/- 226 mg/dl). Serum iron concentration decreased from 134 +/- 13 mg/dl to 83 +/- 11 mg/dl, and percentage saturation decreased from 56 +/- 4 to 41 +/- 5 (p <0.05 in both cases). There were no significant changes in weight, height, blood pressure, caloric intake, triceps skinfold thickness, or arm muscular area. There were also no significant changes in serum calcium, phosphate, bicarbonate, albumin, creatinine, or blood urea nitrogen concentration. Insulin sensitivity increased by 33% (p <0.01), but insulin secretion did not change significantly. Insulin sensitivity during the euglycemic clamp studies in patients before erythropoietin therapy was lower (145 +/- 10 mg/m2 per minute; p <0.01) than published normal values (201 +/- 12 mg/m2 per minute) and was normal after erythropoietin therapy (193 +/- 11 mg/m2 per minute). Insulin secretion was low in patients before erythropoietin therapy (44 +/- 8 microU/ml) compared with published normal values (68 +/- 6 microU/ml) and did not change after erythropoietin therapy (46 +/- 4 microU/ml). Plasma concentrations of branched-chain amino acids and lipids in the patients were compared with values from eight healthy adolescents. Plasma concentrations of valine, leucine, and isoleucine were low before treatment and were normal after 6 months of erythropoietin therapy. Plasma concentrations of triglycerides, total cholesterol, and low-density lipoprotein cholesterol were all high before treatment and were normal after treatment of anemia.
CONCLUSIONS: Treatment of anemia by erythropoietin reversed insulin resistance as well as amino acid and lipid abnormalities in adolescents undergoing dialysis.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8757568     DOI: 10.1016/s0022-3476(96)70195-6

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  13 in total

1.  Association of insulin resistance with arterial stiffness in nondiabetic peritoneal dialysis patients.

Authors:  Erhan Tatar; Meltem Sezis Demirci; Fatih Kircelli; Ozkan Gungor; Mehmet Nuri Turan; Ebru Sevinc Ok; Gulay Asci; Mehmet Ozkahya; Ercan Ok
Journal:  Int Urol Nephrol       Date:  2011-06-04       Impact factor: 2.370

2.  Sex difference in mouse metabolic response to erythropoietin.

Authors:  Yuanyuan Zhang; Heather M Rogers; Xiaojie Zhang; Constance Tom Noguchi
Journal:  FASEB J       Date:  2017-03-10       Impact factor: 5.191

3.  Relation Between Gender and Concomitant Medications With Erythropoietin-Treatment on Wound Healing in Burn Patients. Post Hoc Subgroup-Analysis of the Randomized, Placebo-Controlled Clinical Trial "EPO in Burns".

Authors:  Christina Irene Günter; Felicitas Paula Ilg; Alexander Hapfelmeier; Silvia Egert-Schwender; Wolfgang Jelkmann; Shibashish Giri; Augustinus Bader; Hans-Günter Machens
Journal:  Front Pharmacol       Date:  2022-07-01       Impact factor: 5.988

4.  Management of hyperglycemia in patients with diabetes mellitus and chronic renal failure.

Authors:  Ch Sampanis
Journal:  Hippokratia       Date:  2008-01       Impact factor: 0.471

Review 5.  Insulin and its role in chronic kidney disease.

Authors:  Robert H Mak
Journal:  Pediatr Nephrol       Date:  2007-10-11       Impact factor: 3.714

6.  A novel EPO receptor agonist improves glucose tolerance via glucose uptake in skeletal muscle in a mouse model of diabetes.

Authors:  Michael S Scully; Tatiana A Ort; Ian E James; Peter J Bugelski; Dorie A Makropoulos; Heather A Deutsch; Elsbet J Pieterman; Anita M van den Hoek; Louis M Havekes; William H Dubell; Joshua D Wertheimer; Kristen M Picha
Journal:  Exp Diabetes Res       Date:  2011-06-30

Review 7.  Insulin resistance in patients with chronic kidney disease.

Authors:  Min-Tser Liao; Chih-Chien Sung; Kuo-Chin Hung; Chia-Chao Wu; Lan Lo; Kuo-Cheng Lu
Journal:  J Biomed Biotechnol       Date:  2012-08-07

8.  Comparison of glucose tolerance in renal transplant recipients and hemodialysis patients.

Authors:  Hassan Argani; Alireza Noorazarian; Mohammad Rahbaninobar; Mohammad Noori; Hamid T Khosroshahi
Journal:  BMC Nephrol       Date:  2004-09-08       Impact factor: 2.388

Review 9.  Hypoglycemia in Patients with Diabetes and Renal Disease.

Authors:  Mazen Alsahli; John E Gerich
Journal:  J Clin Med       Date:  2015-05-13       Impact factor: 4.241

Review 10.  Erythropoietin action in stress response, tissue maintenance and metabolism.

Authors:  Yuanyuan Zhang; Li Wang; Soumyadeep Dey; Mawadda Alnaeeli; Sukanya Suresh; Heather Rogers; Ruifeng Teng; Constance Tom Noguchi
Journal:  Int J Mol Sci       Date:  2014-06-10       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.